Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Stable profits, low leverage to keep credit profiles comfortable
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Subscribe To Our Newsletter & Stay Updated
